Encouraging phase 1 results of hypofractionated stereotactic re-irradiation in combination with Durvalumab in recurrent Glioblastoma.
Encouraging phase 1 results of hypofractionated stereotactic re-irradiation in combination with Durvalumab in recurrent Glioblastoma. Durvalumab; deep learning; hypofractionated stereotactic re-irradiation; phase I clinical trial; recurrent glioblastoma; predictive...
Dr Marc Poirot is laureate of the Schroepfer Prize 2023
Talents& awards AWARD Dr Marc Poirot is the winner of the prestigious Schroepfer Prize awarded by the American Oil Chemists’ Society (AOCS), which will be presented to him on 2 May 2023 at the Denver-USA congress. The AOCS is an American learned society...
Fabienne Meggetto awarded by the Amgen France Fund
Talents& Awards AWARD Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma, mainly in children. It accounts for 15% of non-Hodgkin’s lymphomas in children and young adults. Most express a chromosomal translocation involving the ALK gene....
A new target to fight certain aggressive leukaemias
A new target to fight certain aggressive leukaemias Acute Myeloid Leukemia, FLT3, C/AAT-enhancer binding protein α, Jean-Emmanuel Sarry Team METAML- Metabolism and Therapeutic Resistance In Acute Myeloid Leukemia . Researchers from the Toulouse Cancer Research...